ArticlePharmacy (Basel, Switzerland)2024

Evaluating the Risk-Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping Review.

Daniel Hsiang-Te Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.